Table 3.
Risk of sclerosis in patients with chronic GVHD, according to SNPs in donors and recipients
| Genome | Gene | SNP | Alleles* | N | Model | Groups compared | Unadjusted | Adjusted† | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||||||
| Donor | BANK1 | rs10516487 | T/C | 807 | Allelic | TT vs TC vs CC | 0.83 (0.66-1.04) | .11 | 0.84 (0.67-1.05) | .12 |
| Dominant | TT or TC vs CC | 0.91 (0.68-1.20) | .50 | 0.92 (0.69-1.22) | .55 | |||||
| Recessive | TT vs TC or CC | 0.43 (0.21-0.88) | .02 | 0.43 (0.21-0.87) | .02 | |||||
| Donor | CD247 | rs2056626 | G/T | 808 | Allelic | GG vs GT vs TT | 1.23 (1.01-1.51) | .04 | 1.23 (1.00-1.51) | .04 |
| Dominant | GG or GT vs TT | 1.58 (1.14-2.18) | .006 | 1.57 (1.13-2.18) | .007 | |||||
| Recessive | GG vs GT or TT | 1.05 (0.72-1.53) | .82 | 1.04 (0.71-1.53) | .84 | |||||
| Recipient | CD247 | rs2056626 | G/T | 776 | Allelic | GG vs GT vs TT | 1.27 (1.04-1.55) | .02 | 1.24 (1.01-1.52) | .04 |
| Dominant | GG or GT vs TT | 1.62 (1.17-2.24) | .004 | 1.66 (1.19-2.32) | .003 | |||||
| Recessive | GG vs GT or TT | 1.13 (0.78-1.64) | .53 | 1.04 (0.71-1.52) | .85 | |||||
| Donor | HLA-DPA1 | rs987870 | C/T | 793 | Allelic | CC vs CT vs TT | 0.89 (0.66-1.20) | .45 | 0.89 (0.66-1.20) | .44 |
| Dominant | CC or CT vs TT | 0.77 (0.55-1.07) | .12 | 0.76 (0.54-1.06) | .11 | |||||
| Recessive | CC vs CT or TT | 2.44 (1.20-4.96) | .01 | 2.50 (1.22-5.11) | .01 | |||||
| Recipient | HLA-DPA1 | rs987870 | C/T | 767 | Allelic | CC vs CT vs TT | 0.81 (0.59-1.12) | .20 | 0.84 (0.61-1.15) | .28 |
| Dominant | CC or CT vs TT | 0.69 (0.49-0.99) | .04 | 0.72 (0.50-1.03) | .07 | |||||
| Recessive | CC vs CT or TT | 2.17 (1.02-4.63) | .04 | 2.13 (1.00-4.54) | .05 | |||||
*
The first allele is designated as the minor allele and the second allele is designated as the major allele.
†
Adjusted for stem cell graft source, HLA matching, ABO compatibility, TBI dose, and principal components.